One Capital Management LLC decreased its stake in shares of MetLife, Inc. (NYSE:MET - Free Report) by 4.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 124,726 shares of the financial services provider's stock after selling 5,637 shares during the quarter. One Capital Management LLC's holdings in MetLife were worth $10,213,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its holdings in shares of MetLife by 109.2% during the 4th quarter. Bank of New York Mellon Corp now owns 8,826,658 shares of the financial services provider's stock worth $722,727,000 after buying an additional 4,606,748 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in MetLife by 1.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 4,548,725 shares of the financial services provider's stock worth $375,179,000 after acquiring an additional 68,579 shares during the last quarter. Nordea Investment Management AB raised its position in MetLife by 16.8% in the fourth quarter. Nordea Investment Management AB now owns 4,238,087 shares of the financial services provider's stock valued at $347,735,000 after purchasing an additional 608,224 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of MetLife by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,913,408 shares of the financial services provider's stock valued at $320,430,000 after purchasing an additional 30,187 shares during the last quarter. Finally, Swedbank AB grew its holdings in shares of MetLife by 76.0% during the 4th quarter. Swedbank AB now owns 3,466,808 shares of the financial services provider's stock worth $283,862,000 after purchasing an additional 1,496,645 shares during the period. Institutional investors and hedge funds own 94.99% of the company's stock.
Analyst Upgrades and Downgrades
MET has been the topic of several research analyst reports. BMO Capital Markets started coverage on shares of MetLife in a report on Thursday, January 23rd. They issued a "market perform" rating and a $97.00 price objective on the stock. Morgan Stanley boosted their price target on shares of MetLife from $101.00 to $109.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. TD Cowen increased their price objective on shares of MetLife from $97.00 to $99.00 and gave the stock a "buy" rating in a research report on Wednesday, November 27th. Keefe, Bruyette & Woods cut their target price on MetLife from $100.00 to $98.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. upped their price target on MetLife from $86.00 to $88.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 7th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, MetLife currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.58.
Get Our Latest Report on MetLife
MetLife Stock Up 0.1 %
NYSE MET traded up $0.06 on Friday, hitting $82.28. 3,131,884 shares of the stock were exchanged, compared to its average volume of 3,554,516. MetLife, Inc. has a fifty-two week low of $67.30 and a fifty-two week high of $89.05. The company has a 50-day moving average price of $83.72 and a 200-day moving average price of $82.35. The company has a quick ratio of 0.16, a current ratio of 0.16 and a debt-to-equity ratio of 0.54. The company has a market cap of $56.05 billion, a PE ratio of 13.78, a PEG ratio of 0.65 and a beta of 1.04.
MetLife (NYSE:MET - Get Free Report) last issued its earnings results on Wednesday, February 5th. The financial services provider reported $2.08 EPS for the quarter, missing analysts' consensus estimates of $2.13 by ($0.05). MetLife had a return on equity of 20.42% and a net margin of 6.19%. Sell-side analysts anticipate that MetLife, Inc. will post 9.65 EPS for the current fiscal year.
MetLife Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 11th. Stockholders of record on Tuesday, February 4th will be given a dividend of $0.545 per share. This represents a $2.18 annualized dividend and a dividend yield of 2.65%. The ex-dividend date is Tuesday, February 4th. MetLife's dividend payout ratio (DPR) is presently 36.52%.
MetLife Company Profile
(
Free Report)
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Featured Articles

Before you consider MetLife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.
While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.